Dissertation/Thesis Abstract

CAPER as a Novel Therapeutic Target in NSCLC Adenocarcinoma
by Houtmann, Jennifer Lynn, M.S., University of the Sciences in Philadelphia, 2017, 88; 10801757
Abstract (Summary)

Adenocarcinoma, a form of non-small cell lung cancer (NSCLC), is the most commonly diagnosed lung cancer subtype. It comprises some 40% of all diagnoses, and is the most common subtype afflicting women and non-smokers. The negative systemic effects of standard NSCLC chemotherapy and bleak five-year patient survival rates have pushed researchers to explore the use of more targeted treatment engineered towards specific oncogenic molecules. We propose that CAPER, a coactivator of AP-1 and estrogen receptor, could serve as a novel therapeutic target in adenocarcinoma. We found that CAPER was significantly upregulated in patient adenocarcinoma tissue in comparison to normal samples. Additionally, lentiviral-mediated knockdown of CAPER expression in human lung adenocarcinoma cell lines decreased cell number by 60% and significantly increased the survival of mice in an orthotopic xenograft model. This effect can be attributed to G2/M phase cell cycle arrest, the induction of apoptosis, and increased reactive oxygen species.

Indexing (document details)
Advisor:
Commitee:
School: University of the Sciences in Philadelphia
Department: Pharmacology and Toxicology
School Location: United States -- Pennsylvania
Source: MAI 57/05M(E), Masters Abstracts International
Source Type: DISSERTATION
Subjects: Pharmaceutical sciences, Oncology
Keywords: Adenocarcinoma, Ap-1, Apoptosis, Caper, G2/m phase arrest, Nsclc
Publication Number: 10801757
ISBN: 9780355794236
Copyright © 2019 ProQuest LLC. All rights reserved. Terms and Conditions Privacy Policy Cookie Policy
ProQuest